Newsletter | September 5, 2024

09.05.24 -- Why Pharma 4.0 May Not Be Optional For Much Longer

SPONSOR

Webinar: Strategic Antibody Outsourcing: Guidance on Selection, Services, and Facility Fit

Choosing the right CDMO for biologics outsourcing is like finding the perfect fit, balancing capability, and contract terms. Outsourced Pharma's panel from Mabion will share insights on selecting and managing CDMOs, emphasizing facility customization, partnership strategies, RFP optimization, and pricing evaluation. This session aims to guide you in finding a CDMO that meets both immediate and long-term project goals. Click here to learn more.

FEATURED EDITORIAL

VR/XR In Drug Manufacturing: No Longer Sci-Fi

Virtual reality (VR) immerses users in a completely simulated environment, while extended reality (XR) is an umbrella term encompassing VR, augmented reality, and mixed reality. These capabilities open up a world of possibilities for drug manufacturing.

2024 Emerging Trends In Cleanroom Technologies

This article shares new market research on pharma/biotech cleanroom technologies, including regional trends, prominent vendors in the space, and more.

This Takeda Official Thinks Pharma 4.0 Won't Be Optional Much Longer

Advanced technology like automation was once seen only as a competitive advantage. That viewpoint is shifting amid greater reliance on digital technology.

INDUSTRY INSIGHTS

High-Concentration Drug Manufacturing Challenges And Opportunities

The demand for high-concentration/subcutaneous drugs is on the rise. Explore opportunities for enhancing your biotech drug production platform.

Impact Of Glycosylation On The Effector Functions Of Monoclonal Antibodies

In an example using rituximab and its biosimilars, explore the significance of minor differences of glycosylation in antibodies and its impact on their properties and functionality.

NEWS HEADLINES

European Commission Approves Celltrion's SteQeyma (CT-P43), A Biosimilar To Stelara (ustekinumab), For The Treatment Of Multiple Chronic Inflammatory Diseases

Henlius Trastuzumab Receives Approval In Canada

Biocon Biologics Secures Market Entry For Bmab 1200, A Proposed Biosimilar To Stelara, In Europe, UK, Canada, & Japan

Lupin Receives Health Canada Approval For Biosimilar Pegfilgrastim

SOLUTIONS

Optimizing Virus Bank Manufacturing